Literature DB >> 21556287

Targeted maximum likelihood estimation of effect modification parameters in survival analysis.

Ori M Stitelman1, C William Wester, Victor De Gruttola, Mark J van der Laan.   

Abstract

The Cox proportional hazards model or its discrete time analogue, the logistic failure time model, posit highly restrictive parametric models and attempt to estimate parameters which are specific to the model proposed. These methods are typically implemented when assessing effect modification in survival analyses despite their flaws. The targeted maximum likelihood estimation (TMLE) methodology is more robust than the methods typically implemented and allows practitioners to estimate parameters that directly answer the question of interest. TMLE will be used in this paper to estimate two newly proposed parameters of interest that quantify effect modification in the time to event setting. These methods are then applied to the Tshepo study to assess if either gender or baseline CD4 level modify the effect of two cART therapies of interest, efavirenz (EFV) and nevirapine (NVP), on the progression of HIV. The results show that women tend to have more favorable outcomes using EFV while males tend to have more favorable outcomes with NVP. Furthermore, EFV tends to be favorable compared to NVP for individuals at high CD4 levels.

Entities:  

Keywords:  Cox-proportional hazards; G-computation; Targeted Maximum Likelihood Estimation; causal effect; censored longitudinal data; double robust; efficient influence curve; influence curve; semi-parametric; survival analysis

Mesh:

Substances:

Year:  2011        PMID: 21556287      PMCID: PMC3083138          DOI: 10.2202/1557-4679.1307

Source DB:  PubMed          Journal:  Int J Biostat        ISSN: 1557-4679            Impact factor:   0.968


  14 in total

Review 1.  Calculating the number needed to treat for trials where the outcome is time to an event.

Authors:  D G Altman; P K Andersen
Journal:  BMJ       Date:  1999-12-04

2.  Collaborative targeted maximum likelihood for time to event data.

Authors:  Ori M Stitelman; Mark J van der Laan
Journal:  Int J Biostat       Date:  2010       Impact factor: 0.968

3.  Collaborative double robust targeted maximum likelihood estimation.

Authors:  Mark J van der Laan; Susan Gruber
Journal:  Int J Biostat       Date:  2010-05-17       Impact factor: 0.968

4.  Estimating causal effects from epidemiological data.

Authors:  Miguel A Hernán; James M Robins
Journal:  J Epidemiol Community Health       Date:  2006-07       Impact factor: 3.710

5.  Doubly robust estimation in missing data and causal inference models.

Authors:  Heejung Bang; James M Robins
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

6.  Super learner.

Authors:  Mark J van der Laan; Eric C Polley; Alan E Hubbard
Journal:  Stat Appl Genet Mol Biol       Date:  2007-09-16

7.  Comment: Demystifying Double Robustness: A Comparison of Alternative Strategies for Estimating a Population Mean from Incomplete Data.

Authors:  Anastasios A Tsiatis; Marie Davidian
Journal:  Stat Sci       Date:  2007       Impact factor: 2.901

8.  A targeted maximum likelihood estimator of a causal effect on a bounded continuous outcome.

Authors:  Susan Gruber; Mark J van der Laan
Journal:  Int J Biostat       Date:  2010-08-01       Impact factor: 0.968

9.  Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana.

Authors:  C William Wester; Ann Muir Thomas; Hermann Bussmann; Sikhulile Moyo; Joseph M Makhema; Tendani Gaolathe; Vladimir Novitsky; Max Essex; Victor deGruttola; Richard G Marlink
Journal:  AIDS       Date:  2010-01       Impact factor: 4.177

10.  Multiply robust inference for statistical interactions.

Authors:  Stijn Vansteelandt; Tyler J Vanderweele; James M Robins
Journal:  J Am Stat Assoc       Date:  2008-12-01       Impact factor: 5.033

View more
  6 in total

1.  Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial.

Authors:  C William Wester; Ori M Stitelman; Victor deGruttola; Hermann Bussmann; Richard G Marlink; Mark J van der Laan
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-23       Impact factor: 2.205

2.  Scalable collaborative targeted learning for high-dimensional data.

Authors:  Cheng Ju; Susan Gruber; Samuel D Lendle; Antoine Chambaz; Jessica M Franklin; Richard Wyss; Sebastian Schneeweiss; Mark J van der Laan
Journal:  Stat Methods Med Res       Date:  2017-09-22       Impact factor: 3.021

3.  The Appalachia Mind Health Initiative (AMHI): a pragmatic randomized clinical trial of adjunctive internet-based cognitive behavior therapy for treating major depressive disorder among primary care patients.

Authors:  Robert M Bossarte; Ronald C Kessler; Andrew A Nierenberg; Ambarish Chattopadhyay; Pim Cuijpers; Angel Enrique; Phyllis M Foxworth; Sarah M Gildea; Bea Herbeck Belnap; Marc W Haut; Kari B Law; William D Lewis; Howard Liu; Alexander R Luedtke; Wilfred R Pigeon; Larry A Rhodes; Derek Richards; Bruce L Rollman; Nancy A Sampson; Cara M Stokes; John Torous; Tyler D Webb; Jose R Zubizarreta
Journal:  Trials       Date:  2022-06-20       Impact factor: 2.728

4.  Targeted maximum likelihood estimation for prediction calibration.

Authors:  Jordan Brooks; Mark J van der Laan; Alan S Go
Journal:  Int J Biostat       Date:  2012-10-31       Impact factor: 0.968

5.  Improved estimation of the cumulative incidence of rare outcomes.

Authors:  David Benkeser; Marco Carone; Peter B Gilbert
Journal:  Stat Med       Date:  2017-07-02       Impact factor: 2.373

6.  Assessing trends in vaccine efficacy by pathogen genetic distance.

Authors:  David Benkeser; Michal Juraska; Peter B Gilbert
Journal:  J Soc Fr Statistique (2009)       Date:  2020-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.